PFE
NYSE · Pharmaceuticals
Pfizer Inc.
$25.68
-0.80 (-3.02%)
PFE News28 articles
Novavax Shares Surge on Pfizer Deal, Vaccine Strategy Shift
Novavax shares surged 13% Friday after Q1 revenue of $139.5 million beat estimates, fueled by a $30 million Pfizer licensing deal for Matrix-M adjuvant.
Novavax Surges on Pfizer Deal, Q1 Revenue Beat Despite Weak Vaccine Sales
Novavax reported Q1 revenue of $139.5M, beating estimates, driven by $30M from Pfizer's Matrix-M license. Shares rose further as licensing income offset weak COVID vaccine sales.
Novavax Surges on Pfizer Deal, Beats Q1 Revenue Forecasts
Novavax topped Q1 revenue estimates at $139.5M, driven by a $30M Pfizer payment, offsetting weak COVID vaccine sales. Shares rose 15.6%.
Pfizer Q1 Beats Estimates, Patent Cliff Concerns Linger
Pfizer reported Q1 adjusted EPS of $0.75 on $14.45B revenue, beating estimates. Growth in Eliquis and Padcev offset COVID declines, but patent cliff remains a key concern.
Futures Edge Higher as Oil Retreats, JOLTS Data in Focus
U.S. stock futures edged higher Tuesday as oil prices pulled back, with the Nasdaq 100 leading gains ahead of JOLTS data and earnings from AMD, Pfizer, and KKR.
Pfizer and Arvinas Secure First PROTAC Approval in Breast Cancer
The FDA approved Veppanu, a first-of-its-kind PROTAC pill from Pfizer and Arvinas, for advanced breast cancer with ESR1 mutations. The decision precedes Pfizer's Q1 earnings report.
Pfizer Gains on FDA Priority Review for Padcev as Pipeline Pivots Post-COVID
Pfizer shares advanced after the FDA granted priority review for its Padcev bladder cancer therapy, setting an August decision. Investors await Q1 results to gauge progress in oncology and obesity drugs against fading COVID sales.
Major Investors Reduce Pfizer Holdings Amid Growth Transition
Three institutional investors trimmed their Pfizer positions by a combined 740,174 shares in the fourth quarter, filings show, as the pharmaceutical giant navigates its post-pandemic transition.
Pfizer Shares Reach New Peak Amid Divergent Views on Future Growth
Pfizer shares surged to a 52-week high of $28.30, driven by robust quarterly results and promising oncology data. Analysts remain divided on whether the stock's rally is sustainable given looming growth challenges.
Eli Lilly Inks $2.75B AI Drug Deal, Posts Positive Trial Data
Eli Lilly has entered a licensing deal with Insilico Medicine potentially worth $2.75 billion and reported strong late-stage clinical results for its immunology and obesity drugs.
Pfizer Shares Dip as GSK RSV Vaccine Gains Ground, Eliquis Data Provides Support
Pfizer shares declined 1% to $26.60 Friday after GSK secured expanded FDA approval for its RSV vaccine, challenging Pfizer's market position. Encouraging clinical results for blood thinner Eliquis helped cushion the drop.
Pfizer Shares Dip Amid Market Selloff, Weight-Loss Drug Approved in China
Pfizer shares declined 1.6% on Thursday, caught in a broad market downturn. The company navigates falling COVID product revenue while advancing its pipeline, including a new weight-loss drug approval in China.
Pfizer Shares Dip Amid Vaccine Policy Clarity, Eczema Drug Progress
Pfizer shares declined slightly as regulatory scrutiny of mRNA vaccines eased, offset by positive mid-stage trial results for its experimental eczema drug tilrekimig.
J&J Seeks Earlier Use of Tecvayli in Europe Following US Myeloma Approval
Johnson & Johnson has submitted an application to European regulators to expand the use of its myeloma drug Tecvayli as a monotherapy after just one prior treatment. This follows recent U.S. approval for a Tecvayli combination and is supported by trial data showing a 71% reduction in disease progression risk.
Pfizer's Eczema Candidate Tilrekimig Advances, Eyes Dupixent Rivalry
Pfizer announced its experimental eczema drug tilrekimig achieved its main goal in a mid-stage study, showing significant symptom improvement. The company plans to initiate a pivotal Phase 3 trial later this year.
J&J Shares Dip on Lupus Drug Fast Track, Investors Eye Legal Risks
Johnson & Johnson shares declined 0.7% to $245.07 Wednesday after the FDA granted Fast Track designation to its lupus drug candidate nipocalimab, lagging behind a strong market advance.
AbbVie Gains on $8 Billion Bond Sale, Outperforms Slumping Market
AbbVie shares climbed 3.29% to $232.08 on Friday, defying a broader market decline. The pharmaceutical giant is set to raise approximately $7.95 billion through a seven-part bond sale settling March 4.
Merck Shares Rally on Keytruda-Welireg Kidney Cancer Data, Gardasil Job Cuts
Merck shares gained nearly 4% Friday following new clinical data for its Keytruda and Welireg combination in kidney cancer, alongside announced workforce reductions at a Gardasil vaccine facility.
GSK Stock Dips on Ex-Dividend Date and Arexvy Vaccine Data Release
GSK shares declined 0.4% in early London trading, influenced by the stock going ex-dividend and the release of new real-world effectiveness data for its respiratory syncytial virus vaccine Arexvy.
AbbVie Gains Ahead of Holiday; Investors Eye Pipeline and Pricing
AbbVie shares advanced 1.8% to $231.50 in Friday's session, outpacing peers. Trading volume was elevated as investors assess the company's strategic pivot and regulatory challenges.
Pfizer Shares Dip in Premarket Amid SEC Settlement, Partnership News
Pfizer stock edged lower in premarket trading following a $29 million SEC settlement agreement and a new biotech incubator partnership. Investors await key inflation data.
GSK's RSV Vaccine Advances in Chinese Regulatory Review, Eyes 2027 Decision
GSK's Arexvy RSV vaccine application has been accepted for review by China's drug regulator, with a potential approval decision expected in 2027. The stock edged higher as JPMorgan raised its price target and the company's dividend ex-date approaches.
Merck Shares Dip Following Insider Transactions Amid Revenue Forecast Concerns
Merck shares declined 0.5% after SEC filings revealed stock sales by two executives, adding pressure following a revenue outlook that fell short of analyst expectations.
Merck Shares Slide 4% on Patent Concerns and 2026 Outlook
Merck & Co. stock fell nearly 4% Monday, underperforming the broader market as investors reacted to projected patent losses and a cautious 2026 sales forecast.
GSK Nears 52-Week Peak on COPD Drug Approval and U.S. Pricing Developments
GSK shares advanced 0.6% in London trading, approaching a 52-week high following EU approval for Nucala in COPD and amid U.S. drug discount initiatives. Insider trading activity and the upcoming ex-dividend date remain in focus.
Merck Nears 52-Week Peak Amid Insider Sale, Investors Eye Pipeline Updates
Merck shares climbed 1.8% to $121.93, extending gains for a seventh session and approaching a 52-week high. An executive sold 37,685 shares as investors await the impact of 2026 guidance and pipeline developments.
Healthcare Sector Sees Divergence: Molina Plunges on Outlook, XLV Gains Amid Regulatory Warnings
Molina Healthcare plummeted 25.5% after slashing its 2026 profit forecast and announcing a Medicare Part D exit, while the Health Care Select Sector SPDR Fund (XLV) rose 1.8%. Regulatory warnings on compounded obesity drugs added pressure to the sector.
J&J Stock Rises as Court Disqualifies Talc Litigation Firm, AFib Device Data Released
Johnson & Johnson shares gained 0.9% following a New Jersey appeals court decision to remove Beasley Allen from state talc cases and the release of early 12-month data for its investigational AFib device.